Fig. 2From: Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literatureAlluvial diagram showing mentions of the PFS and OS results of TIVO-1 in citing articles. Green: 55.0% publications reported results for both PFS and OS; yellow: 19.2% publications reported neither PFS nor OS; orange: 7.9% publications reported only OS; red: 17.9% reported only PFS. When they are reported, PFS and OS are described in quantitative manner (HR, median or both) in 79.1% [87/110] and 65.3% [62/95]Back to article page